Alembic Pharmaceuticals Ltd Share Price – NSE  /  BSE

Pharmaceuticals, Small Cap

Alembic Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 9 May 2024.

Powered by Capital Market - Live News

The approved drug is generic equivalent to the Kisqali tablets of Novartis Pharmaceuticals Corporation.

Ribociclib tablets are indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)- negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.

Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA.

Alembic Pharmaceuticals is a vertically integrated research and development pharmaceutical company. The company manufactures and markets generic pharmaceutical products all over the world.

The company’s consolidated net profit increased jumped 48.01% to Rs 180.45 crore despite of 8.05% fall in revenue from operations to Rs 1,630.57 crore in Q3 FY24 over Q3 FY23.

Powered by Capital Market - Live News

Alembic Pharmaceuticals has received US Food & Drug administration (USFDA) Product Approval (Tentative) for Ribociclib Tablets, 200 mg.

Ribociclib tablet indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy.

Alembic has a cumulative total of 197 ANDA approvals (170 final approvals and 27 tentative approvals) from USFDA.

Powered by Capital Market - Live News

Alembic Pharmaceuticals announced that the United States Food and Drug Administration (US FDA) has conducted an inspection at its Oncology (Injectable and Oral Solid) Formulation Facility (F-2) at Panelav from 28 February 2024 to 8 March 2024. The US FDA issued a Form 483 with four procedural observations.

The Company will provide comprehensive response to USFDA for the observations within the stipulated period.

Powered by Capital Market - Live News